1. Sax, N. Cancer-causing Chemicals Van Nostrand 1981 / 2. Lancet, June 25, 1977 p1348-9 / 3. The Guardian, July 20, 1991 / 4. Occupational Lung Disorders, Butterworth 1982 / 5. Toxicology & Industrial Health, 1990, vol.6, p293-307 / 6. J Nat Cancer Inst 1969, vol.42, 1045-52 / 7. Br J Cancer, 1947, vol.1, p 192-251 / 8. Advances in Modern Toxicology, vol.2, Wiley, 1977 / 9. J Nat Cancer Inst, 1962, vol.5, p 459 / 10. Fitzgerald, D. The development of new cardiovascular drugs in Recent Developments in Cardiovascular Drugs eds. Coltart and Jewitt, Churchill Livingstone 1981 / 11. Perspectives in Biology & Medicine, 1980 Part 2, S9-S24 / 12. Pharmacy International Feb. 1986; p33-37 / 13. Lancet, i, p 130-2, 1983 / 14. Lancet, 1, no. 8480 p 517-9, March 8, 1996 / 15. Annals of Internal Medicine 1984, vol.101, 667-682 / 16. GAO/PEMD-90-15 FDA Drug Review: Postapproval Risks 1976-1985 / 17. NEJM 333;1099-1105, 1995 / 18. J NIH Res, 1993, 5, 33-35 / 19. Nature, 1993, July 22, p 275 / 20. Nature, 1982, April 1, p 387-90 and Br Med J, 1983, Jan 15, p 199-202 and Drug Monitoring, 1977 and Pharmacologist, 1964, vol. 6, p 12-26 and Pharmacology: Drug Actions and Reac and Advances in Pharm, 1963, vol. 2, 1-112 and Nature, 1982, April 1, p 387-390 / 21. Pharmacologist, 1971, vol.18, p 272 / 22. Br J of Pharm 1969Vol. 36; p35-45 / 23. Inman, W. H. Monitoring for Drug Safety, MTP Press, 1980 / 24. Am Rev Resp Diseases, 1972, vol.105, p883-890 / 25. Lancet, 1979, Oct.27, p 896 / 26. Toxicology and Applied Pharmacology 1965, vol. 7; p1-8 / 27. Animal Toxicity Studies: Their Relevance for Man, Quay Pub. 1990 / 28. Br Med J, 1974, May 18, p 365-366 / 29. Drug Withdrawl from Sale PJB Publications, 1988 / 30. Pharmacology, 1983, vol.27(suppl 1), 87-94 and FDA Drug Review: Postapproval Risks 1976-1985 (US GAO April 1990 / 31. Gut, 1987, vol.28, 515-518 / 32. Lancet, Jan 10, 1987, 113-114 / 33. Toxicolo Letters, 1991, vol.55, p 287-93 /  34. Drug Withdrawl from Sale, PJB1988 / 35. Reg Tox & Pharm,1990,vol.11,288-307 and Postgraduate Med J, 1973, vol.49, April Suppl., 125-129 and 130 / 36. Drugs, 1982, vol.24, p 360-400 / 37. Animal Toxicity Studies Quay, 1990 / 38. Lancet, 1984, July 28, p 219-220 / 39. Matindale: The Extra Pharmacopoeia, 29th edition, Pharmaceutical Press, 1989) / 40. Br Nat Form, no.26, 1993 / 41. Reg Tox & Pharm, 1990, vol.11, p 288-307 / 42. Br Med J, 1983, Jan 15, p 199-202 / 43. Br Nat Form, no.26, 1993 / 44. Tox & Appl Pharm, 1972, vol. 21, p 516-531 / 45. The Benzodiazepines MTP Press1978 / 46. Drugs and Therapeutics Bulletin,1989, vol.27, p 28 / 47. as quoted in Activate For Animals Oct. 1997 The American Antivivisection Society / 48. Parke-Davis letter dated Oct. 31, 1996 / 49. Sneader, W. Drug Discovery: The Evolution of Modern Medicine Wiley, 1985 / 50. Lewis, T. Clinical Science Shaw & Sons Ltd. 1934 / 51. Federation Proceedings 1967, vol.26, 1125-30 / 52. Toxicology In Vitro 1992, vol.6, 47-52 / 53. JAMA, 1990, April 4, p1766 / 54. Lancet,1989, July 22, p 227 / 55. Lancet, 1989, Oct 28, p1000-1004 / 56. Hepatology,1991, vol.13, 1259-1260 / 57. Drugs and Therapeutics Bulletin, 1990, vol.28, p 74-75 / 58. Anesthesiology: Proceedings of the VI World Congress of Anesthesiology, Mexico City 1977 / 59. NEJM, 1987, Sep. 10, p 653-658 / 60. The Causes of Cancer, 1981, Oxford Press / 61. J NIH Res, 1991, vol.3, p46 / 62. Nature, 1991, Feb 28, p732